None
Quote | Sanofi Contingent Value Right (Expiring 12/31/2020) (NASDAQ:GCVRZ)
Last: | $ |
---|---|
Change Percent: | -0.48% |
Open: | $0.8692 |
Close: | $0.8702 |
High: | $0.8744 |
Low: | $0.8692 |
Volume: | 7,273 |
Last Trade Date Time: | 02/12/2020 04:52:07 pm |
News | Sanofi Contingent Value Right (Expiring 12/31/2020) (NASDAQ:GCVRZ)
2024-07-08 12:30:52 ET Summary Eli Lilly and Company is set to acquire Morphic Holding for $3.2bn. Morphic is focused on autoimmune disease drugs. Morphic's MORF-057 has a similar MoA to Takeda's ~$5bn per annum selling drug entyvio, but it is orally available, unlike the injectab...
2024-07-03 06:52:20 ET More on Sanofi, Regeneron, etc. Sanofi's Immunology Business Is Doing A Lot Of Heavy Lifting Sanofi: A Leader In Life-Saving Vaccines And Treatments Regeneron Pharmaceuticals, Inc. (REGN) Goldman Sachs 45th Annual Global Healthcare Conference (...
Message Board Posts | Sanofi Contingent Value Right (Expiring 12/31/2020) (NASDAQ:GCVRZ)
Subject | By | Source | When |
---|---|---|---|
Sanofi announces settlement agreement related to Contingent Value | Enterprising Investor | investorshub | 12/24/2019 8:09:00 PM |
It's been a long time since anyone has | greendragon- | investorshub | 10/25/2019 11:07:24 PM |
New Findings In The $GCVRZ Lawsuit (10/02/18) | Enterprising Investor | investorshub | 11/24/2018 5:55:48 AM |
U.S. District Court | Enterprising Investor | investorshub | 11/24/2018 5:50:03 AM |
Why the volume? What the $ run | JHOGG | investorshub | 01/18/2017 4:38:16 PM |
News, Short Squeeze, Breakout and More Instantly...
Sanofi Contingent Value Right (Expiring 12/31/2020) Company Name:
GCVRZ Stock Symbol:
NASDAQ Market:
Sanofi Contingent Value Right (Expiring 12/31/2020) Website:
* The British Pharmacological Society awards Cablivi® (caplacizumab), the first new treatment in 30 years for acquired Thrombotic Thrombocytopenic Purpura (aTTP), Drug Discovery of the Year 2020 * TTP is a rare blood clotting disorder with 330 people known to be affected i...